Sofinnova Investments

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 272
Average round size
info
The average size of a deal this fund participated in
$25M
Portfolio companies 154
Rounds per year 5.79
Lead investments 49
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 89
Key employees 13
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

Sofinnova Investments is the famous VC, which was founded in 1974. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.

Among the most successful fund investment fields, there are Enterprise Software, Therapeutics. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Spark Therapeutics, Audentes Therapeutics, ZS Pharma. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Sofinnova Investments, startups are often financed by Ventech, Bay City Capital, Vivo Capital. The meaningful sponsors for the fund in investment in the same round are Ventech, New Leaf Venture Partners, Atlas Venture. In the next rounds fund is usually obtained by Ventech, Novartis Venture Fund, Idinvest Partners.

Speaking about the real fund results, this VC is 4 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 7-12 deals per year. This Sofinnova Investments works on 7 percentage points more the average amount of lead investments comparing to the other organizations. When the investment is from Sofinnova Investments the average startup value is 10-50 millions dollars. The top amount of exits for fund were in 2014. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity.

The overall number of key employees were 13.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sofinnova Investments:
Typical Co-investors
Sofinnova Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sofinnova Investments:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Antiva Biosciences

Biotechnology
Health Care
Medical
$31M02 Nov 2021 California, United States

Quanta Therapeutics

Biotechnology
Health Care
Medical Device
Therapeutics
$60M26 Oct 2021 San Francisco, California, United States

CinCor Pharma

Pharmaceutical
Therapeutics
$143M12 Oct 2021 Cincinnati, Ohio, United States

Gyroscope Therapeutics

Biotechnology
Genetics
Health Care
Therapeutics
$147M26 Mar 2021 United Kingdom, England, United Kingdom

Vera Therapeutics

Biotechnology
Health Care
$80M19 Jan 2021 South San Francisco, California, United States

Visen Pharmaceuticals

Biotechnology
Life Science
Pharmaceutical
$150M08 Jan 2021 Shanghai, China

Atsena Therapeutics

Biotechnology
Health Care
Therapeutics
$55M16 Dec 2020 Durham, North Carolina, United States

Aerovate Therapeutics

Biotechnology
Life Science
Medical
$72M06 Aug 2020 Boston, Massachusetts, United States

VelosBio

$137M08 Jul 2020 -
News
Gyroscope Therapeutics Raises $148M in Series C Financing

– Gyroscope Therapeutics from London develops a gene therapy for various eye diseases.
– The company raised $148m in Series C funding.
– The round was led by Forbion’s Growth Opportunities Fund and includes Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Inc., Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
– The company also announced the appointments of Wouter Joustra, General Partner, Forbion and Maha Katabi, General Partner, Sofinnova to the Gyroscope Board of Directors.

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

– XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, today announced the closing of an additional $22.6 million financing.
Fountain Healthcare Partners led the oversubscribed financing joined by new investors Longwood Fund and Lumira Ventures. All existing institutional investors including Sofinnova Investments and LSP (Life Sciences Partners) participated in the financing.
– The additional financing builds upon XyloCor’s 2018 Series A financing round, bringing total investment in the company to $41.9 million to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sofinnova Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: